Novogenia AG

Novogenia AG's next confirmed earnings release is scheduled for March 3, 2027.

As of December 31, 2025, Novogenia AG has 12.00M shares outstanding.

As of December 31, 2025, Novogenia AG maintains a current ratio of 5.81, meaning it holds 5.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 6.15, indicating elevated leverage, while an interest coverage ratio of -12.56 demonstrates limited ability to service its debt obligations.

Over the twelve months ended December 31, 2025, Novogenia AG posted a return on equity (ROE) of 0.53, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) is negative at -2.66, so the business is destroying capital rather than earning a return above its cost of capital. Return on assets (ROA) stands at 0.40, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 0.64, useful for judging operating efficiency across full business cycles. Inventory turnover of 4.01 indicates how many times Novogenia AG sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended December 31, 2025, Novogenia AG recorded 1.50M in income tax expense. That works out to an effective tax rate of 73.31, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 2.04M, leaving 545,465.07 in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

These figures are as of the close on October 22, 2026.

Over the twelve months ended December 31, 2025, Novogenia AG generated 54.30M in revenue and converted that into 545,465.07 in net income, yielding earnings per share of 0.05. EBITDA reached -6.88M, while operating income came in at -10.78M.

As of December 31, 2025, Novogenia AG holds 53.02M in cash and equivalents against 6.15M in total debt, resulting in a net debt position of -6.38M. Total book value stands at 100.16M, with working capital of 62.79M providing operational flexibility.

Novogenia AG produced -12.97M in operating cash flow over the twelve months ended December 31, 2025. After subtracting -8.67M in capital expenditures, free cash flow totaled -21.65M - equivalent to -1.98 per share.

Over the twelve months ended December 31, 2025, Novogenia AG posted a gross margin of 33.84, reflecting its pricing power and cost economics. The operating margin of -19.85 and net profit margin of 1.00 provide insight into operational efficiency.

Over the twelve months ended December 31, 2025, Novogenia AG paid dividends of 0.33 per share. The dividend payout ratio of 656.25 exceeds 100%, meaning the company is distributing more than it earns and funding the dividend from cash reserves, asset sales, or borrowing, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth.

Novogenia AG's most recent stock split took place on September 18, 2025 with a 1:4 split ratio.